<DOC>
	<DOC>NCT00949546</DOC>
	<brief_summary>Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.</brief_summary>
	<brief_title>Treatment of Hidradenitis Suppurativa Using Etanercept</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Chronic HS for &gt; 6months defined as tender and/or painful, red nodules and/or plaques (confluent nodules) with or without scarring, foul odor, or draining sinuses clinically with HS Localizes to skin folds including any of axillx, breast, abdomen and groin active disease Negative pregnancy test within 7 days before the first dose of study drug Sexually active subjects of childbearing potential must agree to use medically acceptable form of contraception during screening and throughout the study Concurrent active infection including tuberculosis Concurrent therapy or therapy 30 days prior with systemic corticosteroids, systemic immunosuppressants, systemic retinoids or antTNF agents Severe comorbidities (diabetes mellitus requiring insulin, Q F of any severity, MI, unstable angina eectoris, uncontrolled hypertension, oxygendependent severe pulmonary disease, history of cancer *thin 5_ years except cutaneous basal cell or squamous cell carcinoma or in situ cervical carcinoma, history of TB or TB exposure, chronic hepatitis B or C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy Currently enrolled or enrolled within 90 days prior in any trial for treatment of HS Known HIV positive Contraindication to etanercept as defined in package insert</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>